	Sensitivity *	False positives *
T21	> 99.9 %, (CI 95 %: 97.1–100 %)	1/1,000, (CI 95 %: ≤ 0.37 %)
T18	> 99.9 %, (CI 95 %: 91.4–100 %)	1/1,000, (CI 95 %: ≤ 0.36 %)
T13	> 99.9 %, (CI 95 %: 87.1–100 %)	1/1,000, (CI 95 %: ≤ 0.36 %)

* Based on a clinical validation study screening > 2,300 maternal samples with Illumina VeriSeq® NIPT-Solution v2

Thanks to its superior performance, Prendia further reduces the risk of unnecessary invasive procedures (such as amniocentesis or chorionic villus sampling) after standard first trimester test (1TT).

Swiss-based

This screening test is performed entirely in our accredited laboratory in Switzerland and any data relating to you and your child remains in Switzerland. Our specialized genetic team is at the disposal of you and your gynecologist.

¹ Pertile MD, Flowers N, Vavrek D, et al. Performance of a paired-end sequencing-based noninvasive prenatal screening test in the detection of genome-wide fetal chromosomal anomalies. Clin Chem. 2021;67(9):121–1219

Discover the Prendia patient brochure

Prendia prenatal test | New price, new turnaround time